FTC Files Suit To Block Amgen’s $28B Buyout Of Horizon Therapeutics

The Federal Trade Commission is suing to stop Amgen’s acquisition of Horizon Therapeutics. But rather than claiming product overlap, the agency contends Amgen will use its influence to keep at bay competition for Horizon’s products.
The post FTC Files Suit To Block Amgen’s $28B Buyout Of Horizon Therapeutics appeared first on Above the Law.
Responses